The latest update is out from CNS Pharmaceuticals (CNSP). CNS Pharmaceuticals, Inc. is engaging with the investment community through a series of meetings, during which they will present information as
The latest update is out from CNS Pharmaceuticals (CNSP). CNS Pharmaceuticals, Inc. is engaging with the investment community through a series of meetings, during which they will present information as
CNS Pharmaceuticals (CNSP) has provided an announcement. CNS Pharmaceuticals, Inc. faces a challenge maintaining its Nasdaq listing after the stock price fell below the $1 minimum bid requirement for 30
CNS Pharmaceuticals (CNSP) has released an update to notify the public and investors about its officers. On January 17, 2024, Amy Mahery was appointed as an independent member of the
CNS Pharmaceuticals (CNSP) has released an update to notify the public and investors about an entry into a material definitive agreement. On January 29, 2024, the Company initiated a public
A.G.P./Alliance Global Partners is acting as the lead placement agent and Maxim Group LLC is acting as the co-placement agent in connection with the offering. Published first on TheFly –